Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.48 |
| ▸ | JAK2 | O60674 | 5/20 | 0.48 |
| ▸ | JAK1 | P23458 | 6/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29540587 | 1.00 | JAK3 (0.48) | JAK3JAK2JAK1BTKBRAF | |
| Trifluoroacetic Acid SCHEMBL4092015 | 0.94 | JAK3 (0.44) | JAK3JAK2JAK1BTKBRAF | |
| SCHEMBL100093 | 0.85 | JAK3 (0.48) | JAK3JAK2JAK1BTKBRAF | |
| SCHEMBL29540508 | 0.85 | JAK3 (0.48) | JAK3JAK2JAK1BTKBRAF | |
| SCHEMBL98624 | 0.82 | MAPK14 (0.47) | BRAFHSD17B10ALDH1A1 | |
| SCHEMBL29540753 | 0.82 | MAPK14 (0.47) | BRAFHSD17B10ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4092161 | 0.80 | JAK3 (0.43) | JAK3JAK2JAK1BTKBRAF | |
| SCHEMBL4092018 | 0.79 | BRAF (0.40) | JAK3BRAFCYP2D6CYP2C9MELK | |
| SCHEMBL100042 | 0.78 | GRM5 (0.57) | JAK3JAK2HSD17B10CDK8 | |
| SCHEMBL29540742 | 0.78 | PRKCI (0.38) | JAK3JAK2BRAFCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | claimed |
| EP-2474545-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-07-11 | — | — | EP | claimed |
| EP-2455382-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2426129-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2012-03-07 | — | — | EP | claimed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | claimed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | claimed |
| EP-1966202-A1 | HETEROARYL SUBSTITUTED PYRROLOÝ2,3-B¨PYRIDINES AND PYRROLOÝ2,3-B¨PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | claimed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | JAK3 2/4885JAK2 4/4885JAK1 1/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | JAK3 1/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.